osteonecrosis of jawquantitative light-induced fluorescenceBackground Recurrence of osteonecrosis of the jaw has been reported after surgery. It is therefore necessary to develop a real-time diagnostic method, which can clearly distinguish the surgical margin from unaffected bone. Methods We analyzed a ...
Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment. While the...
It is well established that alterations in phosphate metabolism have a profound effect on hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the jaw (ONJ) was preceded by phosphorus necrosis of the jaw, ca. 1860.
Medication-related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with anti
Two decades ago, Marx described medication-related osteonecrosis of the jaw (MRONJ) as an emerging clinical entity in patients receiving bisphosphonate therapy [3, 4]. MRONJ is now an established condition defined by exposed bone that can be probed through an intra- or extra-oral fistula(e) ...
Two decades ago, Marx described medication-related osteonecrosis of the jaw (MRONJ) as an emerging clinical entity in patients receiving bisphosphonate therapy [3,4]. MRONJ is now an established condition defined by exposed bone that can be probed through an intra- or extra-oral fistula(e) in...
Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw Article Open access 03 October 2022 Host inflammatory response and clinical parameters around implants in a rat model using systemic alendro...
The present invention relates to methods and compositions for testing individuals to determine whether they are at increased risk of developing anti-resorptive therapy-associated osteonecrosis of the jaw.Inventors: Zavras, Anthanasios (Dover, MA, US) Application...
The femoral head is the most common site of osteonecrosis. Bisphosphonate use is associated with osteonecrosis of the jaw. The final common pathway in the pathogenesis of osteonecrosis is disruption of blood supply to a segment of bone. Abnormalities in lipid metabolism, bone homeostasis, regulation...
Osteonecrosis also occurs with bone-binding antimetabolites, and bisphosphonate osteonecrosis, particularly of the jaw, is an important problem where type and length of treatment affect likelihood of the complication. Sclerotic disorders generally reflect local or systemic changes in bone morphogenetic ...